 |
|
|
| |
Long-term Efficacy and Resistance Analyses of D/C/F/TAF
in the Phase 3 AMBER and EMERALD Studies: Post 96-week Data
|
| |
| |
HIV Glasgow; 23-26 October 2022; Online and Glasgow, UK
Erkki Lathouwers1, Bryan Baugh2, Simon Vanveggel1, Erika Van Landuyt1, Magda Opsomer1, Chloe Orkin3, Joseph J. Eron4
1Janssen Pharmaceutica NV, Beerse, Belgium; 2Janssen Research & Development, LLC, Raritan, NJ, USA; 3Royal London Hospital and Queen Mary University,
Barts Health NHS Trust, London, UK; 4The University of North Carolina School of Medicine, Chapel Hill, NC, USA
|
| |
|
|
|
|
|
